Allogeneic Mesenchymal Stem Cells Restore Endothelial Function in Heart Failure by Stimulating Endothelial Progenitor Cells

EBioMedicine

Volumn 2, Issue 5, 2015, Pages 467-475

  Premer, Courtney ^a   Blum, Arnon ^b   Bellio, Michael A ^a   Schulman, Ivonne Hernandez ^a   Hurwitz, Barry E ^a   Parker, Meela ^a   Dermarkarian, Christopher R ^a   DiFede, Darcy L ^a   Balkan, Wayne ^a   Khan, Aisha ^a   Hare, Joshua M ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b BAR ILAN UNIVERSITY   (Israel)

Author keywords

Autografts; Nitric oxide; Regenerative medicine; Vascular endothelium dependent relaxation; Vasculogenesis

Indexed keywords

NITRIC OXIDE SYNTHASE; VASCULOTROPIN A;

ADULT; ARTICLE; CARDIOVASCULAR FUNCTION; CELL PROLIFERATION; CELL VIABILITY; CLINICAL ARTICLE; COLONY FORMING UNIT; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; ENDOTHELIAL PROGENITOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HEART FAILURE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; ISCHEMIC CARDIOMYOPATHY; MALE; MESENCHYMAL STEM CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); UMBILICAL VEIN ENDOTHELIAL CELL; AGED; ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; CASE CONTROL STUDY; CFU COUNTING; CYTOLOGY; HEMODYNAMICS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLISM; MIDDLE AGED; PARACRINE SIGNALING; PATHOLOGY; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM; VASODILATATION; YOUNG ADULT;

ADULT; AGED; CASE-CONTROL STUDIES; COLONY-FORMING UNITS ASSAY; ENDOTHELIAL PROGENITOR CELLS; ENDOTHELIUM, VASCULAR; FEMALE; HEART FAILURE; HEMODYNAMICS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; PARACRINE COMMUNICATION; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASODILATION; YOUNG ADULT;

EID: 84942420356     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2015.03.020     Document Type: Article

References (39)

1. Asumda F.Z. Age-associated changes in the ecological niche: implications for mesenchymal stem cell aging. Stem Cell Res. Ther. 2013, 4(3):47.
2. Blum A. Heart failure-new insights. Isr. Med. Assoc. J. 2009, 11(2):105-111.
3. Bui A.L., Horwich T.B., Fonarow G.C. Epidemiology and risk profile of heart failure. Nat. Rev. Cardiol. 2011, 8(1):30-41.
4. Cao Y., Gomes S., Rangel E.B., et al. S-nitrosoglutathione reductase-dependent PPARγ denitrosylation participates in adipogenesis and osteogenesis. J. Clin. Investig. 2015, 125(4).
5. Chen L., Tredget E.E., Wu P.Y., Wu Y. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS ONE 2008, 3(4):e1886.
6. Chin B.S.P., Chung N.A.Y., Gibbs C.R., Blann A.D., Lip G.Y.H. Vascular endothelial growth factor and soluble P-selectin in acute and chronic congestive heart failure. Am. J. Cardiol. 2002, 90(11):1258-1260.
7. Corretti M.C., Anderson T.J., Benjamin E.J., et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J. Am. Coll. Cardiol. 2002, 39(2):257-265.
8. Da Silva J.S., Hare J.M. Cell-based therapies for myocardial repair: emerging role for bone marrow-derived mesenchymal stem cells (MSCs) in the treatment of the chronically injured heart. Methods Mol. Biol. 2013, 1037:145-163.
9. Efimenko A., Dzhoyashvili N., Kalinina N., et al. Adipose-derived mesenchymal stromal cells from aged patients with coronary artery disease keep mesenchymal stromal cell properties but exhibit characteristics of aging and have impaired angiogenic potential. Stem Cells Transl. Med. 2014, 3(1):32-41.
10. Eleuteri E., Di Stefano A., Tarro Genta F., et al. Stepwise increase of angiopoietin-2 serum levels is related to haemodynamic and functional impairment in stable chronic heart failure. Eur. J. Cardiovasc. Prev. Rehabil. 2011, 18(4):607-614.
11. Franz Alber H., Dulak J., Frick M., et al. Atorvastatin decreases vascular endothelial growth factor in patients with coronary artery disease. J. Am. Coll. Cardiol. 2002, 39(12):1951-1955.
12. Gnecchi M., Zhang Z., Ni A., Dzau V.J. Paracrine mechanisms in adult stem cell signaling and therapy. Circ. Res. 2008, 103(11):1204-1219.
13. Go A.S., Mozaffarian D., Roger V.L., et al. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 2014, 129(3):e28-e292.
14. Gomes S.A., Rangel E.B., Premer C., et al. S-nitrosoglutathione reductase (GSNOR) enhances vasculogenesis by mesenchymal stem cells. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(8):2834-2839.
15. Hare J.M., Fishman J.E., Gerstenblith G., et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: The POSEIDON randomized trial. JAMA 2012, 308(22):2369-2379.
16. Hatzistergos K.E., Quevedo H., Oskouei B.N., et al. Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ. Res. 2010, 107(7):913-922.
17. Heldman A.W., DiFede D.L., Fishman J.E., et al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. JAMA 2014, 311(1):62-73.
18. Hill J.M., Zalos G., Halcox J.P.J., et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N. Engl. J. Med. 2003, 348(7):593-600.
19. Iyer S.S., Rojas M. Anti-inflammatory effects of mesenchymal stem cells: novel concept for future therapies. Expert. Opin. Biol. Ther. 2008, 8(5):569-581.
20. Karantalis V., Hare J.M. Use of mesenchymal stem cells for therapy of cardiac disease. Circ. Res. 2015, (in Press). 10.1161/CIRCRESAHA.116.303614.
21. Kasper G., Mao L., Geissler S., et al. Insights into mesenchymal stem cell aging: involvement of antioxidant defense and actin cytoskeleton. Stem Cells 2009, 27(6):1288-1297.
22. Marti C.N., Gheorghiade M., Kalogeropoulos A.P., Georgiopoulou V.V., Quyyumi A.A., Butler J. Endothelial dysfunction, arterial stiffness, and heart failure. J. Am. Coll. Cardiol. 2012, 60(16):1455-1469.
23. Mushtaq M., DiFede D., Golpanian S., et al. Rationale and design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (The POSEIDON-DCM Study). J. Cardiovasc. Transl. Res. 2014, 1-12.
24. Quevedo H.C., Hatzistergos K.E., Oskouei B.N., et al. Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(33):14022-14027.
25. Schmidt-Lucke C., Rössig L., Fichtlscherer S., et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 2005, 111(22):2981-2987.
26. Schulman I.H., Zhou M.S., Raij L. Interaction between nitric oxide and angiotensin II in the endothelium: role in atherosclerosis and hypertension. J. Hypertens. Suppl. 2006, 24(1):S45-S50.
27. Shantsila E., Watson T., Lip G.Y. Endothelial progenitor cells in cardiovascular disorders. J. Am. Coll. Cardiol. 2007, 49(7):741-752.
28. Shantsila E., Watson T., Lip G.Y.H. Endothelial progenitor cells in cardiovascular disorders. J. Am. Coll. Cardiol. 2007, 49(7):741-752.
29. Solomon A., Blum A., Peleg A., Lev E.I., Leshem-Lev D., Hasin Y. Endothelial progenitor cells are suppressed in anemic patients with acute coronary syndrome. Am. J. Med. 2012, 125(6):604-611.
30. Stolzing A., Jones E., McGonagle D., Scutt A. Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies. Mech. Ageing Dev. 2008, 129(3):163-173.
31. Telukuntla K.S., Suncion V.Y., Schulman I.H., Hare J.M. The advancing field of cell-based therapy: insights and lessons from clinical trials. J. Am. Heart Assoc. 2013, 2(5).
32. Teraa M., Sprengers R.W., Westerweel P.E., et al. Bone marrow alterations and lower endothelial progenitor cell numbers in critical limb ischemia patients. PLoS ONE 2013, 8(1):e55592.
33. Tsai W.C., Li Y.H., Huang Y.Y., Lin C.C., Chao T.H., Chen J.H. Plasma vascular endothelial growth factor as a marker for early vascular damage in hypertension. Clin. Sci. 2005, 109(1):39-43.
34. Vasa M., Fichtlscherer S., Aicher A., et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ. Res. 2001, 89(1):e1-e7.
35. Wei H., Mao Q., Liu L., et al. Changes and function of circulating endothelial progenitor cells in patients with cerebral aneurysm. J. Neurosci. Res. 2011, 89(11):1822-1828.
36. Werner N., Kosiol S., Schiegl T., et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N. Engl. J. Med. 2005, 353(10):999-1007.
37. Werner N., Wassmann S., Ahlers P., et al. Endothelial progenitor cells correlate with endothelial function in patients with coronary artery disease. Basic Res. Cardiol. 2007, 102(6):565-571.
38. Williams A.R., Hare J.M. Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ. Res. 2011, 109(8):923-940.
39. Zampetaki A., Kirton J.P., Xu Q. Vascular repair by endothelial progenitor cells. Cardiovasc. Res. 2008, 78(3):413-421.